Open AccessNew Possibilities for the Treatment of Crohn’s Disease
Author(s) -
З. А. Мамиева,
Elena Poluektova,
О. С. Шифрин
Publication year - 2019
Publication title -
rossijskij žurnal gastroènterologii, gepatologii, koloproktologii
Language(s) - English
Resource type - Journals
eISSN - 2658-6673
pISSN - 1382-4376
DOI - 10.22416/1382-4376-2019-29-5-13-20
Subject(s) - ustekinumab , crohn's disease , medicine , maintenance therapy , monoclonal antibody , immunogenicity , drug , immunology , disease , monoclonal , placebo , antibody , pharmacology , adalimumab , chemotherapy , pathology , alternative medicine
Aim . To review data on the efficiency and safety of using Ustekinumab in patients with Crohn’s disease. Key findings . Ustekinumab is a fully human monoclonal antibody of the IgG1k class to the p40 subunit of IL-12 and IL-23. The drug interrupts the cascade of humoral and cellular reactions leading to transmural inflammation of the intestinal wall by blocking the interaction of the p40 subunit with the IL-12Rβ1 chain on the surface of T-lymphocytes and NK cells. A number of placebo-controlled studies have demonstrated the effectiveness of Ustekinumab in the induction and the maintenance of remission in those patients with Crohn’s disease who showed no response to conventional therapy (glucocorticosteroids and immunosuppressants) and therapy with TNF-α antagonists. In addition, the efficiency of Ustekinumab in maintaining a clinical response and clinical remission over two years of therapy has been shown. The drug has a favourable safety profile and a low immunogenicity. Conclusion . The reviewed studies show Ustekinumab to be an effective and safe drug for the induction and the maintenance of clinical remission in patients with Crohn’s disease.